Literature DB >> 25014689

Single-pill combination regimens for treatment of HIV-1 infection.

Monica Gandhi, Rajesh T Gandhi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25014689     DOI： 10.1056/NEJMct1215532

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  22 in total

Review 1.  Implementation challenges for long-acting antivirals as treatment.

Authors:  Diane Havlir; Monica Gandhi
Journal:  Curr Opin HIV AIDS       Date:  2015-07       Impact factor: 4.283

Review 2.  Beyond one pill, once daily: current challenges of antiretroviral therapy management in the United States.

Authors:  Mary Clare Masters; Karen M Krueger; Janna L Williams; Lindsay Morrison; Susan E Cohn
Journal:  Expert Rev Clin Pharmacol       Date:  2019-12       Impact factor: 5.045

3.  Single-tablet antiretroviral treatment (once daily).

Authors:  Nisha Andany; Wayne L Gold
Journal:  CMAJ       Date:  2016-05-24       Impact factor: 8.262

Review 4.  [Modern HIV treatment].

Authors:  C Lehmann; J Malin; I Suárez; G Fätkenheuer
Journal:  Internist (Berl)       Date:  2019-04       Impact factor: 0.743

Review 5.  Adherence, resistance, and viral suppression on dolutegravir in sub-Saharan Africa: implications for the TLD era.

Authors:  Suzanne M McCluskey; Toby Pepperrell; Andrew Hill; Willem D F Venter; Ravindra K Gupta; Mark J Siedner
Journal:  AIDS       Date:  2021-12-15       Impact factor: 4.177

6.  Prevalence and Correlates of Reporting Difficulty Taking Antiretroviral Treatment Among HIV-Positive Illicit Drug Users in Vancouver, Canada: A Longitudinal Analysis.

Authors:  Bianca Yeung; N A Mohd Salleh; Eugenia Socías; Huiru Dong; J Shoveller; J S G Montaner; M-J S Milloy
Journal:  AIDS Behav       Date:  2019-05

7.  Effects of Antiviral Drugs on Organic Anion Transport in Human Placental BeWo Cells.

Authors:  Tomohiro Nabekura; Tatsuya Kawasaki; Yuki Kamiya; Yuichi Uwai
Journal:  Antimicrob Agents Chemother       Date:  2015-09-28       Impact factor: 5.191

8.  Switch to Rilpivirine/Emtricitabine/Tenofovir Single-Tablet Regimen of Human Immunodeficiency Virus-1 RNA-Suppressed Patients, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales CO3 Aquitaine Cohort, 2012-2014.

Authors:  Charles Cazanave; Sandrine Reigadas; Cyril Mazubert; Pantxika Bellecave; Mojgan Hessamfar; Fabien Le Marec; Estibaliz Lazaro; Gilles Peytavin; Mathias Bruyand; Hervé Fleury; François Dabis; Didier Neau
Journal:  Open Forum Infect Dis       Date:  2015-03-12       Impact factor: 3.835

9.  Creation of a long-acting rilpivirine prodrug nanoformulation.

Authors:  James R Hilaire; Aditya N Bade; Brady Sillman; Nagsen Gautam; Jonathan Herskovitz; Bhagya Laxmi Dyavar Shetty; Melinda S Wojtkiewicz; Adam Szlachetka; Benjamin G Lamberty; Sruthi Sravanam; Howard S Fox; Yazen Alnouti; Prasanta K Dash; JoEllyn M McMillan; Benson J Edagwa; Howard E Gendelman
Journal:  J Control Release       Date:  2019-09-03       Impact factor: 9.776

Review 10.  Efficacy, safety, and patient acceptability of elvitegravir/cobicistat/emtricitabine/tenofovir in the treatment of HIV/AIDS.

Authors:  Roberta Prinapori; Antonio Di Biagio
Journal:  Patient Prefer Adherence       Date:  2015-08-24       Impact factor: 2.711
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.